5-123I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment

Neurobiology of Aging

Volumn 31, Issue 11, 2010, Pages 1885-1893

  Terrière, Emma ^a   Dempsey, Mary F ^b   Herrmann, Lucie L ^a   Tierney, Kevin M ^a   Lonie, Jane A ^a   O'Carroll, Ronan E ^c   Pimlott, Sally ^d   Wyper, David J ^b   Herholz, Karl ^e   Ebmeier, Klaus P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF STIRLING   (United Kingdom)

^d West of Scotland Radionuclide Dispensary   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer's disease; Amnestic; Dementia; Mild cognitive impairment; Nicotinic acetylcholine receptors; Single photon emission tomography

Indexed keywords

5 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADDENBROOKE COGNITIVE EXAMINATION; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; LIMBIC CORTEX; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; OPTICAL RESOLUTION; PARIETAL LOBE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; REY AUDITORY VERBAL LEARNING TEST; REY COMPLEX FIGURE TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBICULUM; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; AZETIDINES; BRAIN; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIMBIC SYSTEM; MALE; MATCHED-PAIR ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PARAHIPPOCAMPAL GYRUS; PARIETAL LOBE; PILOT PROJECTS; PYRIDINES; RECEPTORS, NICOTINIC; REFERENCE VALUES; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77956909315     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.10.008     Document Type: Article

References (40)

1. Brooks B.L., Iverson G.L., Holdnack J.A., Feldman H.H. Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adults. J. Int. Neuropsychol. Soc. 2008, 14:463-478.
2. Burghaus L., Schutz U., Krempel U., de Vos R.A., Jansen Steur E.N., Wevers A., Lindstrom J., Schroder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res. Mol. Brain Res. 2000, 76:385-388.
3. Cosgrove K.P., Mitsis E.M., Bois F., Frohlich E., Tamagnan G.D., Krantzler E., Perry E., Maciejewski P.K., Epperson C.N., Allen S., O'Malley S., Mazure C.M., Seibyl J.P., van Dyck C.H., Staley J.K. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J. Nucl. Med. 2007, 48:1633-1640.
4. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol. Psychiatry 2001, 49:175-184.
5. Ding Y.S., Fowler J.S., Logan J., Wang G.J., Telang F., Garza V., Biegon A., Pareto D., Rooney W., Shea C., Alexoff D., Volkow N.D., Vocci F. 6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse (New York, NY) 2004, 53:184-189.
6. Dougall N.J., Bruggink S., Ebmeier K.P. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am. J. Geriatr. Psychiatry 2004, 12:554-570.
7. Elser H., Henze M., Spierer F.J., Georgi P. Semiquantitative 99mTc-HMPAO SPECT in dementia of the Alzheimer type: influence of the selection of reconstruction filter and reference region. Nuklearmedizin 1996, 35:243-250.
8. Fujita M., Seibyl J.P., Vaupel D.B., Tamagnan G., Early M., Zoghbi S.S., Baldwin R.M., Horti A.G., Kore N.A., Mukhin A.G., Khan S., Bozkurt A., Kimes A.S., London E.D., Innis R.B. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:183-190.
9. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., Foster N.L., Jack C.R., Galasko D.R., Doody R., Kaye J., Sano M., Mohs R., Gauthier S., Kim H.T., Jin S., Schultz A.N., Schafer K., Mulnard R., van Dyck C.H., Mintzer J., Zamrini E.Y., Cahn-Weiner D., Thal L.J. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch. Neurol. 2004, 61:59-66.
10. Lonie J.A., Herrmann L.L., Donaghey C.L., Ebmeier K.P. Clinical referral patterns and cognitive profile in mild cognitive impairment. Br. J. Psychiatry 2008, 192:59-64.
11. Mamede M., Ishizu K., Ueda M., Mukai T., Iida Y., Fukuyama H., Saga T., Saji H. Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT. J. Nucl. Med. 2004, 45:1458-1470.
12. Martin-Ruiz C., Court J., Lee M., Piggott M., Johnson M., Ballard C., Kalaria R., Perry R., Perry E. Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. Acta Neurol. Scand. Suppl. 2000, 176:34-41.
13. Martin-Ruiz C.M., Court J.A., Molnar E., Lee M., Gotti C., Mamalaki A., Tsouloufis T., Tzartos S., Ballard C., Perry R.H., Perry E.K. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J. Neurochem. 1999, 73:1635-1640.
14. Mathuranath P.S., Nestor P.J., Berrios G.E., Rakowicz W., Hodges J.R. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000, 55:1613-1620.
15. Mitsis E.M., Cosgrove K.P., Staley J.K., Bois F., Frohlich E.B., Tamagnan G.D., Estok K.M., Seibyl J.P., van Dyck C.H. Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2007.12.008.
16. Mitsis E.M., Cosgrove K.P., Staley J.K., Frohlich E.B., Bois F., Tamagnan G.D., Estok K.M., Seibyl J.P., Van Dyck C.H. [123I]5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptor availability in the aging human brain. Ann. NY Acad. Sci. 2007, 1097:168-170.
17. Mukhin A.G., Gundisch D., Horti A.G., Koren A.O., Tamagnan G., Kimes A.S., Chambers J., Vaupel D.B., King S.L., Picciotto M.R., Innis R.B., London E.D. 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol. Pharmacol. 2000, 57:642-649.
18. Nelson H., Willison J. National Adult Reading Test (NART) 1991, Windsor, London.
19. Nordberg A., Lundqvist H., Hartvig P., Andersson J., Johansson M., Hellstrom-Lindahi E., Langstrom B. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement. Geriatr. Cogn. Disord. 1997, 8:78-84.
20. Nordberg A., Lundqvist H., Hartvig P., Lilja A., Langstrom B. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains-in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 1995, 9:21-27.
21. Nordberg A., Winblad B. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 1986, 72:115-119.
22. O'Brien J.T., Colloby S.J., Pakrasi S., Perry E.K., Pimlott S.L., Wyper D.J., McKeith I.G., Williams E.D. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J. Neurol. Neurosurg. Psychiatry 2007, 78:356-362.
23. Perry E., Martin-Ruiz C., Lee M., Griffiths M., Johnson M., Piggott M., Haroutunian V., Buxbaum J.D., Nasland J., Davis K., Gotti C., Clementi F., Tzartos S., Cohen O., Soreq H., Jaros E., Perry R., Ballard C., McKeith I., Court J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur. J. Pharmacol. 2000, 393:215-222.
24. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
25. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
26. Pickut B.A., Dierckx R.A., Dobbeleir A., Audenaert K., Van Laere K., Vervaet A., De Deyn P.P. Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiatry Res. Neuroimaging 1999, 90:103-112.
27. Pimlott S.L., Piggott M., Owens J., Greally E., Court J.A., Jaros E., Perry R.H., Perry E.K., Wyper D. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 2004, 29:108-116.
28. Reitan R.M. Halstead-Reitan Neuropsychological Test Battery 1985, Reitan Neuropsychology Laboratory/Press, Tucson.
29. Rey A. Psychological examination of a case of post-traumatic encephalopathy. Arch. Psychol. 1941, 28:286-340.
30. Rey A. L'examen clinique en psychologie 1964, Presses Universitaires de France, Paris.
31. Sabbagh M.N., Reid R.T., Corey-Bloom J., Rao T.S., Hansen L.A., Alford M., Masliah E., Adem A., Lloyd G.K., Thal L.J. Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. J. Neural. Transm. 1998, 105:709-717.
32. Sabbagh M.N., Reid R.T., Hansen L.A., Alford M., Thal L.J. Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. J. Neural. Transm. 2001, 108:1149-1157.
33. Sabbagh M.N., Shah F., Reid R.T., Sue L., Connor D.J., Peterson L.K., Beach T.G. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch. Neurol. 2006, 63:1771-1776.
34. Sabri O., Kendziorra K., Wolf H., Gertz H.J., Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl. 1):S30-S45.
35. Soonawala D., Amin T., Ebmeier K.P., Steele J.D., Dougall N.J., Best J., Migneco O., Nobili F., Scheidhauer K. Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. NeuroImage 2002, 17:1193-1202.
36. Staley J.K., van Dyck C.H., Weinzimmer D., Brenner E., Baldwin R.M., Tamagnan G.D., Riccardi P., Mitsis E., Seibyl J.P. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J. Nucl. Med. 2005, 46:1466-1472.
37. Terrière E., Sharman M., Donaghey C., Herrmann L., Lonie J., Strachan M., Dougall N., Best J., Ebmeier K.P., Pimlott S., Patterson J., Wyper D. alpha4beta2-Nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis. Neurochem. Res. 2008, 33:643-651.
38. Vaupel D.B., Tella S.R., Huso D.L., Mukhin A.G., Baum I., Wagner V.O., Horti A.G., London E.D., Koren A.O., Kimes A.S. Pharmacology, toxicology, and radiation dosimetry evaluation of [132-I]5-I-A-85380, a radioligand for in vivo imaging of cerebral neuronal nicotinic acetylcholine receptors in humans. Drug Dev. Res. 2003, 58:149-168.
39. Wevers A., Monteggia L., Nowacki S., Bloch W., Schutz U., Lindstrom J., Pereira E.F., Eisenberg H., Giacobini E., de Vos R.A., Steur E.N., Maelicke A., Albuquerque E.X., Schroder H. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur. J. Neurosci. 1999, 11:2551-2565.
40. Yesavage J.A. Geriatric Depression Scale. Psychopharmacol. Bull. 1988, 24:709-711.